PL377506A1 - Przeciwciało (11C7) anty Nogo oraz jego zastosowanie farmaceutyczne - Google Patents

Przeciwciało (11C7) anty Nogo oraz jego zastosowanie farmaceutyczne

Info

Publication number: PL377506A1
Authority: PL; Poland
Prior art keywords: human; binding molecule; antibody; pharmaceutical use; treatment
Prior art date: 2002-12-10

Application number

PL377506A

Other languages

English (en)

Other versions

PL210720B1 (pl

Inventor

Carmen Barske

Anis Khusro Mir

Thomas Oertle

Lisa Schnell

Martin E. Schwab

Alessandra Vitaliti

Mauro Zurini

Original Assignee

Novartis Ag

Universitat Zurich

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-10

Filing date

2003-12-09

Publication date

2006-02-06

2003-12-09 Application filed by Novartis Ag, Universitat Zurich filed Critical Novartis Ag

2006-02-06 Publication of PL377506A1 publication Critical patent/PL377506A1/pl

2012-02-29 Publication of PL210720B1 publication Critical patent/PL210720B1/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Immunology (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL377506A 2002-12-10 2003-12-09 Chimeryczne lub humanizowane przeciwciało monoklonalne lub jego fragmenty F(ab')2 lub Fab, przeciwciało jednołańcuchowe lub przeciwciało pojedynczej domeny zdolne do wiązania się z ludzkim polipeptydem NogoA_632-640, polinukleotyd, wektor ekspresyjny, układ ekspresyjny, izolowana komórka gospodarza, zastosowanie przeciwciała i kompozycja farmaceutyczna PL210720B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0228832.2A GB0228832D0 (en)	2002-12-10	2002-12-10	Organic compound

Publications (2)

Publication Number	Publication Date
PL377506A1 true PL377506A1 (pl)	2006-02-06
PL210720B1 PL210720B1 (pl)	2012-02-29

Family

ID=9949456

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL377506A PL210720B1 (pl)	2002-12-10	2003-12-09	Chimeryczne lub humanizowane przeciwciało monoklonalne lub jego fragmenty F(ab')2 lub Fab, przeciwciało jednołańcuchowe lub przeciwciało pojedynczej domeny zdolne do wiązania się z ludzkim polipeptydem NogoA_632-640, polinukleotyd, wektor ekspresyjny, układ ekspresyjny, izolowana komórka gospodarza, zastosowanie przeciwciała i kompozycja farmaceutyczna

Country Status (24)

Country	Link
US (2)	US7785593B2 (pl)
EP (1)	EP1572745B1 (pl)
JP (1)	JP4504200B2 (pl)
KR (1)	KR101215801B1 (pl)
CN (1)	CN100384877C (pl)
AT (1)	ATE475671T1 (pl)
AU (1)	AU2003289998B2 (pl)
BR (1)	BR0317161A (pl)
CA (1)	CA2509068C (pl)
CY (1)	CY1110848T1 (pl)
DE (1)	DE60333585D1 (pl)
DK (1)	DK1572745T3 (pl)
EC (1)	ECSP055849A (pl)
ES (1)	ES2349293T3 (pl)
GB (1)	GB0228832D0 (pl)
IL (1)	IL169018A (pl)
MX (1)	MXPA05006265A (pl)
NO (1)	NO20053304L (pl)
PL (1)	PL210720B1 (pl)
PT (1)	PT1572745E (pl)
RU (1)	RU2350623C2 (pl)
SI (1)	SI1572745T1 (pl)
WO (1)	WO2004052932A2 (pl)
ZA (1)	ZA200504522B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0228832D0 (en)	2002-12-10	2003-01-15	Novartis Ag	Organic compound
GB0321997D0 (en) *	2003-09-19	2003-10-22	Novartis Ag	Organic compound
NZ548013A (en)	2003-12-22	2009-04-30	Glaxo Group Ltd	Immunoglobulins
CA2614076A1 (en) *	2005-07-05	2007-01-11	Glaxo Group Limited	Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
GB0525662D0 (en)	2005-12-16	2006-01-25	Glaxo Group Ltd	Immunoglobulins
CA2704357C (en) *	2007-11-02	2016-06-21	Novartis Ag	Improved nogo-a binding molecules and pharmaceutical use thereof
CA2730473A1 (en) *	2008-07-11	2010-01-14	Glaxo Group Limited	Novel treatment
US8828390B2 (en)	2010-07-09	2014-09-09	Universitat Zurich	Uses of NOGO-A inhibitors and related methods
IN2014KN02952A (pl)	2012-07-05	2015-05-08	Glaxo Group Ltd
US9534044B2 (en) *	2013-02-28	2017-01-03	United Arab Emirates University	Alpha-synuclein antibodies and uses thereof
US20160135446A1 (en) *	2013-06-13	2016-05-19	Biomatrica, Inc.	Cell stabilization
RU2756275C2 (ru)	2016-03-01	2021-09-29	Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд.	Антитела, специфические к рецептору полиовируса (pvr) человека
KR20220082007A (ko)	2019-10-08	2022-06-16	넥틴 테라퓨틱스 리미티드	폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
BR112022006534A2 (pt) *	2019-10-24	2022-07-05	Novago Therapeutics Ag	Anticorpos anti-nogo-a
WO2026041734A1 (en)	2024-08-22	2026-02-26	Novago Therapeutics Ag	Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308573D0 (en)	1983-03-29	1983-05-05	British Nuclear Fuels Ltd	Filament impregnating/coating
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
EP0281604B1 (en)	1986-09-02	1993-03-31	Enzon Labs Inc.	Single polypeptide chain binding molecules
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en)	1989-08-30	1993-01-19	Barde Yves Alain	Brain-derived neurotrophic factor
AU658396B2 (en)	1991-03-06	1995-04-13	Merck Patent Gesellschaft Mit Beschrankter Haftung	Humanized and chimeric monoclonal antibodies
JP2002522016A (ja)	1998-07-22	2002-07-23	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ
SK287323B6 (sk)	1998-11-06	2010-07-07	University Of Z�Rich	Nogo proteín, jeho purifikovaný fragment, chimérny proteín a purifikovaná molekula s jeho obsahom, izolovaná nukleová kyselina, vektor s jej obsahom, rekombinantná bunka, spôsob produkcie rekombinantného proteínu a jeho použitie
CU22921A1 (es)	1999-11-16	2004-02-20	Centro Inmunologia Molecular	Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
HUP0203863A3 (en)	2000-01-12	2008-03-28	Univ Yale	Nogo receptor-mediated blockade of axonal growth
AU2002258808A1 (en) *	2001-04-30	2002-11-11	Eli Lilly And Company	Humanized antibodies
DE20110806U1 (de)	2001-06-29	2001-12-20	Jack Wolfskin Ausrüstung für Draussen GmbH, 65510 Idstein	Zelt
EP2990394A1 (en) *	2001-11-30	2016-03-02	Biogen MA Inc.	Antibodies against monocyte chemotactic proteins
GB0228832D0 (en)	2002-12-10	2003-01-15	Novartis Ag	Organic compound
NZ548013A (en)	2003-12-22	2009-04-30	Glaxo Group Ltd	Immunoglobulins
US7596225B2 (en) *	2005-06-30	2009-09-29	Alcatl-Lucent Usa Inc.	Method for refreshing a pairwise master key

2002
- 2002-12-10 GB GBGB0228832.2A patent/GB0228832D0/en not_active Ceased
2003
- 2003-12-09 BR BR0317161-2A patent/BR0317161A/pt active Search and Examination
- 2003-12-09 DK DK03782350.7T patent/DK1572745T3/da active
- 2003-12-09 PL PL377506A patent/PL210720B1/pl unknown
- 2003-12-09 MX MXPA05006265A patent/MXPA05006265A/es active IP Right Grant
- 2003-12-09 US US10/538,201 patent/US7785593B2/en not_active Expired - Fee Related
- 2003-12-09 RU RU2005121669/13A patent/RU2350623C2/ru not_active IP Right Cessation
- 2003-12-09 PT PT03782350T patent/PT1572745E/pt unknown
- 2003-12-09 CN CNB2003801096228A patent/CN100384877C/zh not_active Expired - Fee Related
- 2003-12-09 AT AT03782350T patent/ATE475671T1/de active
- 2003-12-09 JP JP2004558049A patent/JP4504200B2/ja not_active Expired - Fee Related
- 2003-12-09 CA CA2509068A patent/CA2509068C/en not_active Expired - Fee Related
- 2003-12-09 EP EP03782350A patent/EP1572745B1/en not_active Expired - Lifetime
- 2003-12-09 ES ES03782350T patent/ES2349293T3/es not_active Expired - Lifetime
- 2003-12-09 AU AU2003289998A patent/AU2003289998B2/en not_active Ceased
- 2003-12-09 KR KR1020057010410A patent/KR101215801B1/ko not_active Expired - Fee Related
- 2003-12-09 WO PCT/EP2003/013960 patent/WO2004052932A2/en not_active Ceased
- 2003-12-09 SI SI200331887T patent/SI1572745T1/sl unknown
- 2003-12-09 DE DE60333585T patent/DE60333585D1/de not_active Expired - Lifetime
2005
- 2005-06-06 IL IL169018A patent/IL169018A/en not_active IP Right Cessation
- 2005-06-10 EC EC2005005849A patent/ECSP055849A/es unknown
- 2005-07-06 NO NO20053304A patent/NO20053304L/no not_active Application Discontinuation
2006
- 2006-02-08 ZA ZA200504522A patent/ZA200504522B/en unknown
2010
- 2010-06-18 US US12/819,060 patent/US8535666B2/en not_active Expired - Fee Related
- 2010-10-19 CY CY20101100934T patent/CY1110848T1/el unknown

Also Published As

Publication number	Publication date
PL210720B1 (pl)	2012-02-29
JP4504200B2 (ja)	2010-07-14
KR101215801B1 (ko)	2012-12-26
GB0228832D0 (en)	2003-01-15
NO20053304L (no)	2005-09-07
AU2003289998A1 (en)	2004-06-30
DK1572745T3 (da)	2010-10-25
US7785593B2 (en)	2010-08-31
KR20050095768A (ko)	2005-09-30
JP2006523087A (ja)	2006-10-12
RU2350623C2 (ru)	2009-03-27
BR0317161A (pt)	2005-11-01
CA2509068A1 (en)	2004-06-24
MXPA05006265A (es)	2005-12-05
CA2509068C (en)	2012-02-07
US8535666B2 (en)	2013-09-17
HK1084676A1 (en)	2006-08-04
PT1572745E (pt)	2010-10-21
IL169018A (en)	2012-07-31
CY1110848T1 (el)	2015-06-10
CN1747971A (zh)	2006-03-15
US20110059110A1 (en)	2011-03-10
WO2004052932A2 (en)	2004-06-24
ATE475671T1 (de)	2010-08-15
SI1572745T1 (sl)	2010-12-31
RU2005121669A (ru)	2007-01-20
EP1572745B1 (en)	2010-07-28
US20060183678A1 (en)	2006-08-17
ECSP055849A (es)	2005-09-20
WO2004052932A3 (en)	2004-10-21
EP1572745A2 (en)	2005-09-14
CN100384877C (zh)	2008-04-30
AU2003289998B2 (en)	2008-02-14
DE60333585D1 (de)	2010-09-09
ES2349293T3 (es)	2010-12-29
ZA200504522B (en)	2006-03-29
NO20053304D0 (no)	2005-07-06

Publication	Publication Date	Title
CY1110848T1 (el)	2015-06-10	Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
ECSP056263A (es)	2006-04-19	Anticuerpos humanizados que reconocen el péptido beta amiloideo
CA2501984A1 (en)	2004-04-29	Erythropoietin receptor binding antibodies
BG111652A (en)	2014-03-31	Antibodies against the receptor of insulin-like growth factor i
MX2010004915A (es)	2010-05-27	Anticuerpos para gdf8 asi como sus usos.
NO20062289L (no)	2006-08-03	Antigen bindende molekyler med oket FC reseptor bindende affinitet og effektor funksjon
MX2009013824A (es)	2010-04-12	Proteinas de enlace de antigeno que enlazan par-2.
EA200700136A1 (ru)	2007-08-31	Анти-cd154-антитела
BRPI0715660B8 (pt)	2021-05-25	anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
CA2256308A1 (en)	1997-12-04	Antibodies to the ed-b domain of fibronectin, their construction and uses
UA89017C2 (uk)	2009-12-25	ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
IL168058A (en)	2013-05-30	Antibody preferentially linked to cell Ca125 / 0722p relative to ca125 / 0722p deciduous cell, the pharmaceutical composition containing it and its use in the preparation of a drug
WO2005018424A3 (en)	2006-04-27	Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2006087637A3 (en)	2006-10-12	Anti her2/neu antibody
TW200720439A (en)	2007-06-01	Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
TW200635946A (en)	2006-10-16	Binding proteins specific for human matriptase
PE20250753A1 (es)	2025-03-13	Inmunoconjugados de il-2 atenuada-anticuerpo anti-pd-1 y usos de los mismos
WO2006083964A3 (en)	2009-04-30	Modified fusion molecules for treatment of allergic disease
WO2007039256A3 (de)	2007-07-05	Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
PE20090981A1 (es)	2009-08-13	Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas
BRPI0407031A (pt)	2006-01-17	Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
TW200517123A (en)	2005-06-01	Nogo-A binding molecules and pharmaceutical use thereof
ATE312921T1 (de)	2005-12-15	Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
Boysen et al.	2001	The metal binding properties of the CCCH motif of the 50S ribosomal protein L36 from Thermus thermophilus: Authors' affiliations
WO2022223970A3 (en)	2022-12-01	Method and composition